Jupiter Neurosciences regains Nasdaq minimum bid price compliance

JUPITER NEUROSCIENCES, INC.

Nasdaq confirmed compliance on July 9, 2025 after closing bid price ≥ $1.00 for 13 consecutive days (June 18 – July 8, 2025).
Company had been notified of deficiency on March 21, 2025 with a 180-day cure period ending September 17, 2025.
Nasdaq considers the matter closed; common stock (JUNS) continues listing on Nasdaq Capital Market.
Jupiter is a clinical-stage pharma developing JOTROL resveratrol platform for CNS disorders and longevity products.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.